Asset
TEGOPRUBART
ELEDON PHARMACEUTICALS INC. COMMON STOCK
Revenue
No revenue reported in loaded filings.
Clinical trials (5)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06126380 | phase2 | enrolling_by_invitation | 2023-10-25 | 2029-12-01 | Eledon Pharmaceuticals | Long-Term Safety and Efficacy of Tegoprubart in Kidney Transplant Recipients |
| NCT05125068 | phase2 | terminated | 2022-03-21 | 2023-07-31 | Eledon Pharmaceuticals | Safety and Efficacy of AT-1501 in Patients With IgA Nephropathy (IgAN) |
| NCT05983770 | phase2 | completed | 2023-08-30 | 2025-09-11 | Eledon Pharmaceuticals | Safety and Efficacy of Tegoprubart in Patients Undergoing Kidney Transplantation |
| NCT05027906 | phase1_2 | recruiting | 2022-02-18 | 2027-01-01 | Eledon Pharmaceuticals | Safety, Pharmacokinetics, and Efficacy of AT 1501 in Patients Undergoing Kidney Transplant |
| NCT07835581 | phase3 | not_yet_recruiting | 2026-10-01 | 2029-03-01 | Eledon Pharmaceuticals | Study of Tegoprubart Efficacy and Safety Compared With Tacrolimus in Kidney Transplantation |
FDA applications (0)
This company has no applications containing this asset.